559 related articles for article (PubMed ID: 29266965)
1. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
[TBL] [Abstract][Full Text] [Related]
2. Overuse of long-acting β
Brunton SA; Hogarth DK
Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
[TBL] [Abstract][Full Text] [Related]
3. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
4. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
7. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
8. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
9. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.
Wise RA; Scirica BM; Bhatt DL; Daoud SZ; Chuecos F; Garcia Gil E; Chapman KR
Adv Ther; 2021 Oct; 38(10):5381-5397. PubMed ID: 34528220
[TBL] [Abstract][Full Text] [Related]
12. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
[TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Spencer S; Evans DJ; Karner C; Cates CJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status.
Reilev M; Kristensen KB; Søndergaard J; Henriksen DP; Thompson W; Pottegård A
Eur J Clin Pharmacol; 2019 Jul; 75(7):1025-1032. PubMed ID: 30903196
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
[TBL] [Abstract][Full Text] [Related]
16. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Noninferiority Trial Comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study.
Park SY; Kim S; Kim JH; Kim SH; Lee T; Yoon SY; Kim MH; Moon JY; Yang MS; Jung JW; Kim JH; Choi JH; Park CS; Kim S; Lee J; Kwon JW; Hur GY; Kim SH; Kim HK; Shin YS; Kim SH; Nam YH; Jang AS; Park SY; Kim TB;
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1304-1311.e2. PubMed ID: 33184024
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
Suissa S; Dell'Aniello S; Ernst P
Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
[TBL] [Abstract][Full Text] [Related]
19. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
Oba Y; Chandran AV; Devasahayam JV
COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
[TBL] [Abstract][Full Text] [Related]
20. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
